| Bioactivity | Bleselumab (ASKP 1240) is a human anti-CD40 monoclonal antibody (mAb). Bleselumab binds to human CD40 with high affinity (Kd: 0.24 nM). Bleselumab inhibits immune responses by blocking the interaction of CD40 with its ligand CD40L. Bleselumab prevents organ transplant rejection[1]. |
| Target | CD40 |
| Invitro | Bleselumab (0-1 μg/mL, 48 h) dose-depently inhibits PBMCs proliferation induced by soluble CD154[2]. Cell Viability Assay[2] Cell Line: |
| In Vivo | Bleselumab (0.1-10 mg/kg, i.v.) inhibits Delayed-type hypersensitivity (DTH) reaction in cynomolgus monkeys[2].Bleselumab (2 mg/kg, i.v.) prolongs renal allograft survival in Cynomolgus monkeys[3].Bleselumab (2 or 5 mg/kg, i.v.) together with Tacrolimus (HY-13756) shows a longer median survival time (MST) than monotherapy[3]. Animal Model: |
| Name | Bleselumab |
| CAS | 1453067-91-8 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Harland RC, et al. Efficacy and safety of bleselumab in kidney transplant recipients: A phase 2, randomized, open-label, noninferiority study. Am J Transplant. 2020 Jan;20(1):159-171. [2]. Okimura K, et al. Characterization of ASKP1240, a fully human antibody targeting human CD40 with potent immunosuppressive effects. Am J Transplant. 2014 Jun;14(6):1290-9. [3]. Song L, et al. Effects of ASKP1240 combined with tacrolimus or mycophenolate mofetil on renal allograft survival in Cynomolgus monkeys. Transplantation. 2014 Aug 15;98(3):267-76. |